Older white males with advanced bladder cancer more likely to commit suicide
the ONA take:
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers, according to a recent study published in Cancer.
Zachary Klaassen, MD, of the Medical College of Georgia at Georgia Regents University and fellow researchers looked through the NCI’s SEER database from 1988 to 2010 and identified 1.2 million patients with cancer of the prostate, bladder, kidney, testes, and penis. They examined variables such as age, sex, race, as well as the aggressiveness of both the disease and treatment.
Their findings stressed suicide as a matter of public concern that requires physician awareness among men with genitourinary cancers. In particular, patients who were older, male and have more aggressive disease were found to be the most likely to commit suicide.
“The older, white, single male is already at higher risk in the general society for suicide,” Dr. Klaassen said. “Add on the fact that he has advanced bladder cancer and this is a high-risk patient. But this has taught me that we have to look for warning signs in all these patients.”
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|